| | | | |
P
|
|---|
|
Biomarkers (unit)
|
Remission median (range)
|
No Change median (range)
|
Progression median (range)
|
R+NC vs P
|
R vs NC+P
|
|---|
|
VEGF BV1 (pg/mL)
|
364.0 (136.6-868.0)
|
180.5 (70.6-546.0)
|
286.4 (72.6-522.6)
|
0.589
|
0.083
|
|
VEGF BV2 (pg/mL)
|
144.0 (34.6-588.4)
|
237.8 (52.1-431.0)
|
325.2 (158.4-612.1)
|
0.001
|
0.016
|
|
VEGF BV3 (pg/mL)
|
119.0 (26.0-571.0)
|
269.7 (51.0-526.0)
|
402.8 (174.6-811.0)
|
0.001
|
0.001
|
|
VEGF BV1-2 (Dec%)
|
41.6 (2.2-86.8)
|
-6.6 (-90.6-64.5)
|
-18.5 (-118.2-2.7)
|
0.0001
|
0.0001
|
|
VEGF BV1-3 (Dec%)
|
63.0 (17.2-93.1)
|
-3.2 (-142.2-53.0)
|
-41.0 (-140.5- -17.8)
|
0.0001
|
0.0001
|
|
VEGF BV2-3 (Dec%)
|
12.7 (-62.4-87.1)
|
-21.2 (-33.6-33.8)
|
-15.3 (-66.3-5.3)
|
0.0268
|
0.0052
|
- BV1, BV2, and BV3, baseline VEGF levels before therapy cycle 1 to 3, respectively; BV1-2, BV1-3 and BV2-3, kinetics of baseline VEGF levels from cycles 1 to 2, 1 to 3 and 2 to 3, respectively; Dec%, decrease in percent (negative numbers meaning increase of the VEGF levels). P values by Wilcoxon test indicate differences between patients with progressive disease (P) and those having remission and stable disease (R+NC; evaluation 1) as well as between patients with remission (R) and those having progressive and stable disease (P+NC; evaluation 2).
